Optimisation of Monitoring for Clinical Research Studies (OPTIMON)

This study has been completed.
Sponsor:
Information provided by:
University Hospital, Bordeaux
ClinicalTrials.gov Identifier:
NCT00780091
First received: May 21, 2008
Last updated: August 11, 2010
Last verified: August 2010
  Purpose

OPTIMON will compare the efficacy and the cost of two monitoring strategies: one based on the classic standards of quality assurance, and the other one being a priori "optimized" on the main scientific and regulatory principles.


Condition Intervention
Healthy
Other: classical monitoring strategy
Other: optimized monitoring strategy

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Evaluation of Efficacy and Cost of Two Monitoring Strategies for Public Clinical Research - OPTIMON: Optimisation of Monitoring for Clinical Research Studies

Further study details as provided by University Hospital, Bordeaux:

Primary Outcome Measures:
  • Proportion of patients' file without severe error. [ Time Frame: at end of follow-up ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Compounds of the main outcome, other errors, delay to get the results, costs [ Time Frame: at end of follow-up ] [ Designated as safety issue: No ]

Estimated Enrollment: 1800
Study Start Date: May 2008
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
classical monitoring strategy
Other: classical monitoring strategy
intensive on-site monitoring, consistently with the pharmaceutical industry practices
2
optimized monitoring strategy
Other: optimized monitoring strategy
optimized on-site monitoring, depending on patient's risk

Detailed Description:

There is no validated standard of monitoring strategy for clinical research studies. Optimon will compare two monitoring strategies - a classical strategy based on the practices of the pharmaceutical industry, and an optimized strategy based on patient's risk level - on their ability to produce exact data, focusing on the main quality criteria: regulatory requirements and scientific validity of results. Optimon is a non inferiority randomized trial.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

All type of patients enrolled in the eligible studies

Criteria

Inclusion Criteria:

  • Clinical Research Studies: risk level A, B, or C in the Optimon risk-assessment scale, with or without a sponsor and the advice of an ethical committee, starting in 2008 and ending before the end of 2010, with a foreseen accrual of 20 patients or more, multicentric with at least 4 clinical sites, with a paper or electronic CRF, with the participating agreement of the coordinating investigator and the sponsor.
  • Clinical sites: Sites with a foreseen accrual of 5 patients at least, with the participating agreement of the principal investigator.
  • Clinical Research Units: with the label of an institution, with at least 2 years of experience in multicentric studies, with SOPs finalized before 2008, willing to participate in Optimon.

Exclusion Criteria:

  • N/A
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00780091

Locations
France
Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique du CHU de Bordeaux
Bordeaux, France, 33076
Sponsors and Collaborators
University Hospital, Bordeaux
Investigators
Study Director: Geneviève CHENE, MD, PhD University Hospital, Bordeaux
  More Information

Publications:
Responsible Party: Jean-Pierre LEROY / Clinical Research and Innovation Director, University hospital, Bordeaux
ClinicalTrials.gov Identifier: NCT00780091     History of Changes
Other Study ID Numbers: CHUBX 2005/04
Study First Received: May 21, 2008
Last Updated: August 11, 2010
Health Authority: France: Ministry of Health

Keywords provided by University Hospital, Bordeaux:
optimization
risk scale
non inferiority
cluster randomization
monitoring strategies

ClinicalTrials.gov processed this record on July 22, 2014